US pharmaceutical firm Pfizer has sold off its remaining stake in Sensodyne and Panadol maker Haleon for around £2.5 billion. Haleon has agreed to buy back 44 million shares from Pfizer for £3. ...

GSK's main partner in the consumer health joint venture that became Haleon – Pfizer – holds the remaining 32% in the new company and has said that it will sell its stake now that the ...

The UK ECM market has been held up by a handful of large block trades, including two accelerated bookbuild offerings of more ...

Deal volume fell by 24 per cent to its lowest level since mid-2020, despite predictions of a surge in activity in the wake of ...

Rosebank Industries raised £1.14bn in a rights issue on Friday in a rare large equity deal in London this year. The ...

According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, ...

The UK pharma group – now a therapeutics and vaccines pure-play since the spin-off of Haleon in July – also ... to market ahead of a rival jab from Pfizer, which is also anticipating ...

She pointed to several other trials of methotrexate in both hand and knee OA that showed little to no benefit, and that in ...

Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Pfizer is licensing a promising investigational cancer medicine from a smaller company. This move improves the drugmaker's already attractive oncology pipeline. Pfizer should eventually bounce ...

On Tuesday, BNP Paribas (OTC: BNPQY) Exane initiated coverage on Haleon Plc (NYSE: HLN), a $50.3 billion consumer healthcare company, with an Outperform rating and a price target of $13.40.The ...